Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06741644 · ClinicalTrials.gov registry record · Phase 1
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
A Phase 1 study, sponsored by CStone Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 660
- Enrollment target
NCT06741644 is a Phase 1 study that is actively recruiting participants, run by CStone Pharmaceuticals. The registered enrollment target is 660 participants.
The verdict
NCT06741644, a Phase 1 study, is actively recruiting participants, sponsored by CStone Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 660 participants
- Enrollment target
Study Summary
This is a first-in-human (FIH), open-label, and multi-center Phase I/II study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of CS2009 as Monotherapy and Combination Therapy in Participants with Advanced Solid Tumors. The study is comprised of a Phase I dose escalation and Phase II dose expansion.
Interventions
- DRUG Carboplatin
- DRUG Pemetrexed
- DRUG Paclitaxel
- DRUG CS2009
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 660 participants |
| Start Date | 2025-02-24 |
| Est. Completion | 2028-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06741644
The ClinicalTrials.gov registry entry for NCT06741644 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 660 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CStone Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Carboplatin is the first listed.
NCT06741644 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06741644 about?
NCT06741644 is a clinical study titled "A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors". This is a first-in-human (FIH), open-label, and multi-center Phase I/II study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of CS2009 as Monotherapy and Combination Therapy in Participants with Advanced Solid Tumors. The study is comprised of a ...
What is the current status of trial NCT06741644?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 660 participants. The study started on 2025-02-24. Estimated completion is 2028-01.
What interventions are being tested in trial NCT06741644?
The interventions under investigation include: Carboplatin (DRUG), Pemetrexed (DRUG), Paclitaxel (DRUG), CS2009 (DRUG).
Who is sponsoring clinical trial NCT06741644?
This trial is sponsored by CStone Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.